IP Library Granted Patent US 7,067,557
Granted Patent B2
US 7,067,557 · App. 10/081,098 · Granted Jun 27, 2006

Methods of treating androgen deficiency in men using selective antiestrogens

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,067,557
App. No.
10/081,098
Granted
Jun 27, 2006
Kind
B2
Abstract

The administration of antiestrogens to men suffering a relative androgen deficiency stimulates the body's production of testosterone leading to a correction of the deficiency. For example, male menopause, loss of cognitive function, insulin resistance, type 2 diabetes, obesity, excessive weight, Alzheimer's disease, and combinations thereof, can all be characterized by significant decreases in serum levels of bioavailable androgens. Administration of antiestrogens to men restores optimum serum levels of bioavailable androgens, and, thus, serves as a treatment for these disorders and relative androgen deficiency in general.

Claims (11)

1. A method for treating a decline in cognitive function related to male menopause in men comprising administering a selective antiestrogen.

2. A method for treating Alzheimer's disease related to male menopause in men comprising administering a selective antiestrogen.

3. A method for treating insulin resistance related to male menopause in men comprising administering a selective antiestrogen.

4. A method for treating weight gain related to male menopause comprising administering a selective antiestrogen.

5. A method for treating type 2 diabetes related to male menopause comprising administering a selective antiestrogen.

6. The method according to claim 1 , 2 , 3 , 4 , or 5 , wherein the selective antiestrogen is tamoxifen.

7. The method according to claim 1 , 2 , 3 , 4 , or 5 , wherein the selective antiestrogen is tamoxifen citrate.

8. The method according to claim 1 , 2 , 3 , 4 , or 5 , wherein the selective antiestrogen is clomiphine.

9. The method according to claim 1 , 2 , 3 , 4 , or 5 , wherein the selective antiestrogen is clomiphine citrate.

10. The method according to claim 9 , wherein the clomiphine citrate comprises the cis isomer.

11. The method according to claim 9 , wherein the clomiphine citrate comprises the trans isomer.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 2, 2018
From: BMO HARRIS BANK N.A.
To: ASPEN PARK PHARMACEUTICALS, INC.
Reel/Frame 045090/0402 →
SECURITY INTEREST Recorded Dec 8, 2016
From: ASPEN PARK PHARMACEUTICALS, INC.
To: BMO HARRIS BANK N.A.
Reel/Frame 040597/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2016
From: MILLENNIUM SCIENCES INC.
To: ASPEN PARK PHARMACEUTICALS, INC.
Reel/Frame 040290/0647 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2016
From: MILLENNIUM SCIENCES INC.
To: ASPEN PARK PHARMACEUTICALS, INC.
Reel/Frame 040120/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2016
From: FISCH, HARRY
To: MILLENNIUM SCIENCES INC.
Reel/Frame 040477/0461 →
Continuity (4)
Continuation In Part 0998065200 · Oct 26, 2001
Continuation PCTUS011590000 · May 15, 2001
Provisional Application 6020749600 · May 26, 2000
Related Publication 20020120012A1 · Aug 29, 2002